Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 71.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,127 shares of the company’s stock after selling 57,199 shares during the quarter. Jane Street Group LLC’s holdings in Zymeworks were worth $339,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC grew its stake in Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares in the last quarter. AlphaQuest LLC grew its stake in Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after purchasing an additional 2,324 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Zymeworks by 343.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after purchasing an additional 7,518 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Zymeworks in the 4th quarter worth approximately $151,000. Finally, New York State Common Retirement Fund grew its position in shares of Zymeworks by 42.7% in the 4th quarter. New York State Common Retirement Fund now owns 13,371 shares of the company’s stock worth $196,000 after acquiring an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc bought 320,690 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were purchased at an average price of $11.49 per share, with a total value of $3,684,728.10. Following the purchase, the director now directly owns 16,040,851 shares of the company’s stock, valued at approximately $184,309,377.99. The trade was a 2.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have acquired 1,405,768 shares of company stock valued at $16,773,032 in the last quarter. Corporate insiders own 1.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZYME. Lifesci Capital began coverage on Zymeworks in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 target price for the company. TD Securities began coverage on Zymeworks in a research report on Tuesday, May 20th. They issued a “buy” rating for the company. TD Cowen began coverage on Zymeworks in a research report on Tuesday, May 20th. They issued a “buy” rating for the company. HC Wainwright lifted their target price on Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, March 10th. Finally, Citigroup lifted their target price on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Trading Up 2.8%

Shares of NYSE ZYME opened at $11.67 on Monday. The company has a market cap of $811.96 million, a price-to-earnings ratio of -7.78 and a beta of 1.24. Zymeworks Inc. has a 12-month low of $8.21 and a 12-month high of $17.70. The stock’s 50 day simple moving average is $11.61 and its 200 day simple moving average is $13.08.

Zymeworks (NYSE:ZYME) last announced its earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $27.11 million for the quarter, compared to the consensus estimate of $20.65 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm’s revenue for the quarter was up 170.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.42) EPS. As a group, equities analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current fiscal year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.